New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The partnership also sets the stage for broader collaboration on rare disease treatments
Subscribe To Our Newsletter & Stay Updated